自身免疫性和炎性疾病的人源化抗CD4单克隆抗体疗法。
Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.
作者信息
Isaacs J D, Burrows N, Wing M, Keogan M T, Rebello P R, Watts R A, Pye R J, Norris P, Hazelman B L, Hale G, Waldmann H
机构信息
Cambridge University Department of Pathology, UK.
出版信息
Clin Exp Immunol. 1997 Nov;110(2):158-66. doi: 10.1111/j.1365-2249.1997.tb08312.x.
We have investigated the biological and therapeutic properties of a humanized anti-CD4 MoAb, hIgG1-CD4, in patients with refractory psoriasis and rheumatoid arthritis (RA). hIgG1-CD4 is a modulating, non-depleting MoAb, which induced a first-dose reaction in most patients treated. It provided brief symptomatic relief in both conditions, and psoriasis appeared easier to control with conventional agents after MoAb therapy. At the doses used, hIgG1-CD4 did not synergize therapeutically with the panlymphocyte MoAb CAMPATH-1H (C1H) in patients with RA treated sequentially with both agents. There were no serious adverse effects definitely attributable to therapy. Our results are compared with those of other CD4 MoAb studies, and factors influencing the outcome of therapy are discussed.
我们研究了人源化抗CD4单克隆抗体hIgG1-CD4在难治性银屑病和类风湿关节炎（RA）患者中的生物学特性和治疗特性。hIgG1-CD4是一种调节性而非耗竭性单克隆抗体，在大多数接受治疗的患者中引发了首剂反应。它在这两种病症中均提供了短暂的症状缓解，并且在单克隆抗体治疗后，银屑病似乎更易于用传统药物控制。在所使用的剂量下，hIgG1-CD4在先后接受两种药物治疗的RA患者中，与全淋巴细胞单克隆抗体CAMPATH-1H（C1H）在治疗上没有协同作用。没有明确归因于治疗的严重不良反应。我们将结果与其他CD4单克隆抗体研究的结果进行了比较，并讨论了影响治疗结果的因素。
Zotero 插件